

Mats JÄnsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4326111/publications.pdf>

Version: 2024-02-01

22
papers

694
citations

567281

15
h-index

713466

21
g-index

23
all docs

23
docs citations

23
times ranked

1898
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome. <i>Clinical Cancer Research</i> , 2014, 20, 6127-6140.	7.0	91
2	Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations. <i>Urology</i> , 2015, 86, 1212-1217.	1.0	74
3	Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer. <i>Oncotarget</i> , 2015, 6, 22028-22037.	1.8	61
4	Immunohistochemistry in the Differential Diagnostics of Primary Lung Cancer. <i>American Journal of Clinical Pathology</i> , 2013, 140, 37-46.	0.7	56
5	Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. <i>BMC Urology</i> , 2016, 16, 15.	1.4	52
6	Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 34796-34810.	1.8	45
7	Global Transcriptional Changes Following Statin Treatment in Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3402-3411.	7.0	44
8	Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1257-1267.	1.1	43
9	Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. <i>Nature Cancer</i> , 2021, 2, 1224-1242.	13.2	37
10	Distinct Gene Expression Signatures in Lynch Syndrome and Familial Colorectal Cancer Type X. <i>PLoS ONE</i> , 2013, 8, e71755.	2.5	28
11	CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma. <i>PLoS ONE</i> , 2017, 12, e0186284.	2.5	26
12	Molecular subtype classification of urothelial carcinoma in Lynch syndrome. <i>Molecular Oncology</i> , 2018, 12, 1286-1295.	4.6	25
13	Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence. <i>Acta Oncologica</i> , 2019, 58, 1079-1086.	1.8	18
14	Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor. <i>BMC Clinical Pathology</i> , 2009, 9, 8.	1.8	17
15	A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer. <i>Scientific Reports</i> , 2019, 9, 5207.	3.3	17
16	Molecular Subtyping of Serous Ovarian Tumors Reveals Multiple Connections to Intrinsic Breast Cancer Subtypes. <i>PLoS ONE</i> , 2014, 9, e107643.	2.5	17
17	Immunoprofiles of colorectal cancer from Lynch syndrome. <i>Oncolimmunology</i> , 2019, 8, e1515612.	4.6	14
18	Comprehensive analysis of RNA binding motif protein 3 (RBM3) in non-small cell lung cancer. <i>Cancer Medicine</i> , 2020, 9, 5609-5619.	2.8	10

#	ARTICLE	IF	CITATIONS
19	A gene expression-based single sample predictor of lung adenocarcinoma molecular subtype and prognosis. <i>International Journal of Cancer</i> , 2021, 148, 238-251.	5.1	10
20	Analysis of human papillomaviruses and human polyomaviruses in lung cancer from Swedish never-smokers. <i>Acta Oncologica</i> , 2020, 59, 28-32.	1.8	4
21	Clinical Utility of Targeted Sequencing in Lung Cancer: Experience From an Autonomous Swedish Health Care Center. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100013.	1.1	4
22	Detection of Non-Small Lung Cell Carcinoma-Associated Genetic Alterations Using a NanoString Gene Expression Platform Approach. <i>Methods in Molecular Biology</i> , 2021, 2279, 91-107.	0.9	0